1.-Epidemiology of autoimmune diseases (mainly rheumatoid arthritis (RA), giant cell arteritis, scleroderma, spondyloarthropathies (EspA), systemic lupus erythematosus (SLE), psoriasis, antisynthetic syndrome, interstitial lung disease, Shöenlein-Henoch purpura PSH), aortitis, fibromyalgia and hidradenitis suppurativa). We analyze incidence, clinical spectrum and evolutionary course of these diseases. In many cases, these data are unknown in the Spanish population, which puts our center as a reference for the knowledge of these diseases in southern European population.
2.- Cardiovascular risk (CV) and vascular disease in autoimmune diseases (mainly RA, EspA, SLE, psoriasis and hidradenitis suppurativa). Role of inflammation and genetics in their development and clinical presentation. We analyzed the markers (analytical, clinical and imaging) associated with inflammation that may be involved in the development of CV events and early mortality in patients with chronic inflammatory rheumatologic diseases.
3.- Genetic, serum and gene expression profiles of autoimmune diseases and their associated comorbidities (mainly RA, giant cell arteritis, scleroderma, EspA, SLE, psoriasis, antisynthetic syndrome, interstitial lung disease, aortitis and PSH). Study of the genetic predisposition pattern of susceptibility as well as analysis of serum biomarkers and gene expression profiles in rheumatologic autoimmune inflammatory diseases and their associated comorbidities.
4.- Therapeutic strategy with biological agents in patients with autoimmune diseases (mainly RA, EspA and psoriasis). Effect on clinical parameters of the disease and the development of CV disease. Based strictly on clinical indication for lack of response to conventional standard therapy, in those patients that due to the severity of the disease require biological treatments, we analyze the impact of these therapies on the progression of atherosclerotic disease, analyzing serum markers and clinical parameters Associated with an increased risk of CV mortality and the implication of these drugs in their pathogenesis as potentially "protective" therapies against the development of CV disease progression.
5- Role of endothelial progenitor cells in the pathophysiology of interstitial lung disease associated with rheumatoid arthritis